The anti-MIgG(Fc)-C-MMAE ADC is a sophisticated antibody-drug conjugate (ADC) designed for targeted cancer therapy. This ADC combines an anti-MIgG antibody, which specifically binds to the Fc region of mouse immunoglobulin G (IgG), with the potent cytotoxic agent monomethyl auristatin E (MMAE). The targeted approach allows the ADC to deliver MMAE directly to cancer cells, minimizing damage to healthy tissues and enhancing the efficacy of the treatment. Anti-MIgG(Fc)-C-MMAE ADCs are particularly valuable in preclinical research involving murine models, allowing for the precise evaluation of therapeutic strategies in mouse studies before advancing to human clinical trials.